# US 2008/0188432 A1 · Oligomeric compounds for the modulation ras expression

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2008/0188432 A1
- Document ID: US20080188432A1
- Status: Published application
- Kind: A1
- Application number: 11/640,123
- Filed: 2006-12-15
- Published: 2008-08-07
- Earliest claimed: 2003-02-10
- Inventors: Bo Hansen; Charlotte Albaek Thrue; Majken Westergaard; Kamille Dumong Petersen; Margit Wissenbach
- Web page: https://patentgrep.com/patent/US20080188432A1

## CPC

- C12N 15/1135: {against oncogenes or tumor suppressor genes}
- A61P 1/04: for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A61P 1/18: for pancreatic disorders, e.g. pancreatic enzymes
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A61P 11/00: Drugs for disorders of the respiratory system
- A61P 11/06: Antiasthmatics
- A61P 13/08: of the prostate
- A61P 13/10: of the bladder
- A61P 13/12: of the kidneys
- A61P 15/00: Drugs for genital or sexual disorders (for disorders of sex hormones A61P5/24); Contraceptives
- A61P 17/00: Drugs for dermatological disorders
- A61P 17/06: Antipsoriatics
- A61P 17/12: Keratolytics, e.g. wart or anti-corn preparations
- A61P 19/02: for joint disorders, e.g. arthritis, arthrosis
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 27/02: Ophthalmic agents
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 31/12: Antivirals
- A61P 35/00: Antineoplastic agents
- A61P 37/08: Antiallergic agents (antiasthmatic agents A61P11/06; ophthalmic antiallergics A61P27/14)
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07H 21/04: with deoxyribosyl as saccharide radical
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- C12N 2310/11: Antisense
- C12N 2310/31: of the backbone
- C12N 2310/315: Phosphorothioates
- C12N 2310/3231: having an additional ring, e.g. LNA, ENA
- C12N 2310/33: of the base
- C12N 2310/3341: 5-Methylcytosine
- C12N 2310/341: Gapmers, i.e. of the type ===---===
- C12N 2310/346: having a combination of backbone and sugar modifications
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07H: SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS (derivatives of aldonic or saccharic acids C07C, C07D; aldonic acids, saccharic acids C07C59/105, C07C59/285; cyanohydrins C07C255/16; glycals C07D; compounds of unknown constitution C07G; polysaccharides, derivatives thereof C08B; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification C12N15/00; sugar industry C13)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

Oligonucleotides directed against the Ha-ras gene are provided for modulating the expression of Ha-ras. The compositions comprise oligonucleotides, particularly antisense oligonucleotides, targeted to nucleic acids encoding the Ha-ras. Methods of using these compounds for modulation of Ha-ras expression and for the treatment of diseases associated with either overexpression of Ha-ras, expression of mutated Ha-ras or both are provided. Examples of diseases are cancer such as lung, breast, colon, prostate, pancreas, lung, liver, thyroid, kidney, brain, testes, stomach, intestine, bowel, spinal cord, sinuses, bladder, urinary tract or ovaries cancers. The oligonucleotides may be composed of deoxyribonucleosides or a nucleic acid analogue such as for example locked nucleic acid or a combination thereof.

## Claims

### Claim 1

A compound consisting of a total of 8-50 nucleotides and/or nucleotide analogues, wherein said compound comprises a subsequence of at least 8 nucleotides or nucleotide analogues, said subsequence being located within SEQ ID NO 15.

### Claim 2 (depends on 1)

A compound of according to claim 1, which modulates the expression of ras selected from Ha-ras, Ki-ras or N-ras.

### Claim 3

A compound consisting of a total of 8-50 nucleotides and/or nucleotide analogues targeted to a nucleic acid molecule encoding Ha-ras, wherein said compound specifically hybridises with a nucleic acid encoding Ha-ras and inhibits the expression of Ha-ras and wherein said compound comprises a subsequence of at least 8 nucleotides or nucleotide analogues, said subsequence being located within SEQ ID NO 15.

### Claim 4 (depends on 1, 2, 3)

The compound according to any of claims 1-3, which is an antisense oligonucleotide.

### Claim 5 (depends on 4)

The compound according to claim 4, comprising at least 1 nucleotide analogue.

### Claim 6 (depends on 5)

The compound according to claim 5, comprising at least one Locked Nucleic Acid (LNA) unit.

### Claim 7 (depends on 6)

The compound according to claim 6, wherein the Locked Nucleic Acid (LNA) has the structure of the general formula
X and Y are independently selected among the groups —O—, —S—, —N(H)—, N(R)—, —CH2— or —CH— (if part of a double bond), —CH2—O—, —CH2—S—, —CH2—N(H)—, —CH2—N(R)—, —CH2—CH2— or —CH2—CH— (if part of a double bond), —CH═CH—, where R is selected form hydrogen and C1-4-alkyl; Z and Z* are independently absent, selected among an internucleoside linkage, a terminal group or a protecting group;
B constitutes a natural or non-natural nucleobase;
and the asymmetric groups may be found in either orientation.

### Claim 8 (depends on 6)

The compound according to claim 6, wherein at least one nucleotide comprises a Locked Nucleic Acid (LNA) unit according any of the formulas
wherein Y is —O—, —S—, —NH—, or N(RH); Z and Z* are independently absent, selected among an internucleoside linkage, a terminal group or a protecting group; and B constitutes a natural or non-natural nucleobase.

### Claim 9 (depends on 6)

The compound according to claim 6, wherein the internucleoside linkage may be selected from the group consisting of —O—P(O)2—O—, —O—P(O,S)—O—, —O—P(S)2—O—, —S—P(O)2—O—, —S—P(O,S)—O—, —S—P(S)2—O—, —O—P(O)2—S—, —O—P(O,S)—S—, —S—P(O)2—S—, —O—PO(RH)—O—, O—PO(OCH3)—O—, —O—PO(NRH)—O—, —O—PO(OCH2CH2S—R)—O—, —O—PO(BH3)—O—, —O—PO(NHRH)—O—, —O—P(O)2—NRH—, —NRH—P(O)2—O—, —NRH—CO—O—, where RH is selected form hydrogen and C1-4-alkyl.

### Claim 10 (depends on 5)

The compound according to claim 5, wherein the nucleobases is a modified nucleobases selected from the group consisting of 5-methylcytosine, isocytosine, pseudoisocytosine, 5-bromouracil, 5-propynyluracil, 6-aminopurine, 2-aminopurine, inosine, diaminopurine, 2-chloro-6-aminopurine.

### Claim 11 (depends on 6)

The compound according to claim 6, wherein the LNA is oxy-LNA, thio-LNA, amino-LNA, in either the D-β or L-α configurations or combinations thereof.

### Claim 12

A compound consisting of a total of 8-50 nucleotides and/or nucleotide analogues, wherein said compound comprises a subsequence of at least 8 nucleotides or nucleotide analogues, said subsequence being located within the sequence set forth as SEQ ID NO: 15.

### Claim 13 (depends on 1)

The compound according to claim 1, wherein the antisense oligonucleotide is a design according to any of the designs presented in FIG. 1.

### Claim 14 (depends on 12)

The compound according to claim 12, wherein the antisense oligonucleotide is a gapmer.

### Claim 15 (depends on 1)

The compound according to claim 1, wherein the antisense oligonucleotide comprises 13, 14, 15, 16, 17, 18, 19, 20 or 21 nucleotides.

### Claim 16 (depends on 1)

The compound according to claim 1, comprising 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20 or 21 LNA units.

### Claim at position 17

17-29. (canceled)

### Claim 30 (depends on 1)

The compound according to claim 1, wherein the subsequence is SEQ ID NO: 132.

### Claim at position 19

31-44. (canceled)

### Claim 45

A compound consisting of SEQ ID NO: 132.

### Claim at position 21

46-49. (canceled)

### Claim 50 (depends on 45)

The compound according to claim 45, wherein the 3′ end LNA is replaced by the corresponding nucleotide.

### Claim 51 (depends on 1, 50)

A conjugate comprising the compound according to claims 1 or 50 and at least one non-nucleotide or non-polynucleotide moiety covalently attached to said compound.

### Claim 52 (depends on 1, 51)

A pharmaceutical composition comprising a compound as defined in any of claims 1 50 or a conjugate as defined in claim 51, and a pharmaceutically acceptable diluent, carrier or adjuvant.

### Claim 53 (depends on 51)

The pharmaceutical composition according to claim 51 further comprising at least one chemotherapeutic agent.

### Claim 54 (depends on 52)

The pharmaceutical composition according to claim 52, wherein said chemotherapeutic compound is selected from the group consisting of adrenocorticosteroids, such as prednisone, dexamethasone or decadron; altretamine (hexylen, hexamethylmelamine (HMM)); amifostine (ethyol); aminoglutethimide (cytadren); amsacrine (M-AMSA); anastrozole (arimidex); androgens, such as testosterone; asparaginase (elspar); bacillus calmette-gurin; bicalutamide (casodex); bleomycin (blenoxane); busulfan (myleran); carboplatin (paraplatin); carmustine (BCNU, BiCNU); chlorambucil (leukeran); chlorodeoxyadenosine (2-CDA, cladribine, leustatin); cisplatin (platinol); cytosine arabinoside (cytarabine); dacarbazine (DTIC); dactinomycin (actinomycin-D, cosmegen); daunorubicin (cerubidine); docetaxel (taxotere); doxorubicin (adriomycin); epirubicin; estramustine (emcyt); estrogens, such as diethylstilbestrol (DES); etopside (VP-16, VePesid, etopophos); fludarabine (fludara); flutamide (eulexin); 5-FUDR (floxuridine); 5-fluorouracil (5-FU); gemcitabine (gemzar); goserelin (zodalex); herceptin (trastuzumab); hydroxyurea (hydrea); idarubicin (idamycin); ifosfamide; IL-2 (proleukin, aldesleukin); interferon alpha (intron A, roferon A); irinotecan (camptosar); leuprolide (lupron); levamisole (ergamisole); lomustine (CCNU); mechlorathamine (mustargen, nitrogen mustard); melphalan (alkeran); mercaptopurine (purinethol, 6-MP); methotrexate (mexate); mitomycin-C (mutamucin); mitoxantrone (novantrone); octreotide (sandostatin); pentostatin (2-deoxycoformycin, nipent); plicamycin (mithramycin, mithracin); prorocarbazine (matulane); streptozocin; tamoxifin (nolvadex); taxol (paclitaxel); teniposide (vumon, VM-26); thiotepa; topotecan (hycamtin); tretinoin (vesanoid, all-trans retinoic acid); vinblastine (valban); vincristine (oncovin) and vinorelbine (navelbine).

### Claim 55 (depends on 1)

A pharmaceutical composition comprising the compound of claim 1, which further comprises a pharmaceutically acceptable carrier.

### Claim 56 (depends on 1)

A pharmaceutical composition comprising the compound of claim 1, which is employed in a pharmaceutically acceptable salt.

### Claim 57 (depends on 1)

A pharmaceutical composition comprising the compound of claim 1, which constitutes a pro-drug.

### Claim 58 (depends on 1)

A pharmaceutical composition comprising the compound of claim 1, which further comprises an antiinflammatory compounds and/or antiviral compounds.

### Claim at position 31

59-93. (canceled)
